Davita Inc vs Target Corporation — how do they compare? Davita Inc trades at $228.71 (market cap $14.92B), while Target Corporation trades at $139.5 (market cap $60.86B). The key difference: Target Corporation is far larger — about 4.1× Davita Inc's market cap, and Target Corporation pays a 3.46% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | TGT | |
|---|---|---|
Market Cap | $14.92B | $60.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $235.71 | $141.19 |
52-Week Low | $103.87 | $83.68 |
Enterprise Value | $27.47B | $76.16B |
Dividend Yield | — | 3.46% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Target (TGT) trades at $134.77, down 0.27% today, with a bullish technical signal from moving averages and a neutral oscillator stance. The company maintains stable revenue around $106.6 billion (2025) and has beaten earnings estimates for three consecutive quarters. Recent dividend payments of $1.14 and $1.16 per share highlight its shareholder returns, while analyst consensus leans toward a buy rating with a $137 price target.
TGT presents a balanced opportunity with solid fundamentals and moderate valuation, but faces risks from competitive retail pressures and margin compression. Upside is supported by consistent earnings beats and dividend reliability, though investors should monitor consumer spending trends and inventory management challenges.
Trailing returns across standard periods
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →